OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
Issued by the Japanese Patent OfficeA New Protection Covering Tedopi® Until 2037 NANTES, France, Jan….